calendar earn season kick
calendar earn season biopharma servic compani includ
contract research organ contract develop manufactur
organ cdmo begin octob icon plc iclr report overal
cro/cdmo industri fundament remain solid trim estim
fx headwind provid current think health icon plc iclr
ia west pharma four controversi name
cro rise tide lift boat posit trend abound
concurr earn preview conduct cro industri updat
revisit cro competit landscap follow wave activ
last coupl year review cro industri fundament continu
see favor trend across indic driver cro industri includ
biotech financ robust drug pipelin activ see cro industri
fundament chart given posit cro industri fundament
remain bullish see biopharma industri consolid project delay
cancel and/or repriorit execut risk potenti near-term risk
still outgrow cro peer top cro pick
earlier year suffer coupl custom project cancel
combin difficult prior-year comparison result organ revenu growth
slow high-teen high-singl digit
organ growth moder still grow cro market estimate
cro peer view warrant premium also believ
prah organ growth acceler low-doubl digit start driven
win recent prefer partnership new partnership win
anoth oncology-partnership expand anoth therapeut area
cancel work come back lastli encourag manag recent
focu intern system effici drive sg leverag help
ebitda margin even compani grow fast reiter top pick buy
iclr data end site also matter
iclr controversi name week competitor initi sell
rate patient recruit capabl primari differenti among
name acquir patient data asset potenti
mine recruit patient trial effect bear case iclr assert
could lose share shield away big data acquisit view
note iclr data compani access million
patient record partnership watson trinetx instead
buy data iclr build clinic site network believ
site-driven recruit strategi inferior data-driven recruit base
consult recruit expert site physician relationship access
identifi patient data use readili enrol patient trial
reiter buy iclr
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
posit ta capit deploy option
upgrad neutral buy last quarter believ recent win rate
 oce competit win quarterli award net book-to-bil capit
deploy help improv growth next year link technolog
analyt ta segment shown consist mid-singl digit organ revenu
growth last three quarter think may sustain recent
invest tuck-in deal product launch oce continu bear fruit
said differenti view bull
stock acknowledg recent improv cro/r busi
remain reserv near-term benefit data-driven next-gen offer
note think data end patient recruit
believ next-gen still proof-of-concept stage far far
perceiv concret financi effect next-gen posit backlog
metric mute revenu growth recent next-gen win convert
revenu later neg margin see next-gen particularli
fix price contract anoth form price competit innov product like
next-gen also typic margin dilut implement phase due
necessari continu invest custom gener hesit pay
offer begin proclaim benefit suffici
demonstr summari believ data analyt potenti
transform drug develop also think street might bullish
time
maintain po reiter under-perform
reiter cautiou view think compani continu
under-perform organ revenu growth margin expans target near
term biggest opportun under-perform thesi work
unsustain pharma spike continu soft biolog lower-
than-expect oper margin expans lower-margin contract
manufactur product segment continu outgrow proprietari product
 continu margin pressur segment higher start-up cost
unabsorb overhead cost unfavor mix tool revenu biggest
fundament risk thesi out-performance segment
lumpi busi could get unexpect big lump order high-
valu product hvp time driven customer-specif inventori manag
tabl calendar earn schedul bofaml-cov biopharma servic compani
tba announc
mn
overview estim po chang
prah guidanc end base euro rate
gbp rate current euro rate gbp rate
given tweak total revenu estimate vs
prior estimate adj ep estimate vs prior estimate fx said
full year revenu adj ebitda adj ep estim remain
higher reimburs expens revenu offset fx headwind
make chang estim po iclr
tabl summari estim po chang
tabl summari estim po chang
price object base adj ebitda estim
premium peer given compani leadership softgel market improv
organ sale growth potenti upsid risk integr risk low
capac util lumpi sale constrain drug spend regul
price object base adj ep estim
premium peer believ multipl warrant compani
lead preclin cro continu gain market share diversifi
enhanc growth profil seri deal risk price object
integr risk constrain drug spend retrench outsourc declin
use anim model preclin overcapac sponsor consolid competit
price object base ep estim premium
multipl believ warrant given compani strong biopharma strateg
partnership diversifi custom base solid execut higher qualiti earn
mostli risk po custom concentr sponsor consolid soft
 spend competit technolog risk execut risk regulatori risk
price object base adj ep estim multipl
slight premium histor averag price-to-earnings think warrant
posit current cro industri trend risk price object lower
biopharma commerci spend custom consolid data suppli secur
risk competit technolog risk execut risk regulatori risk
price object base adj ep estim multipl
premium cro peer believ warrant better reflect compani
near-term above-averag core sale earn growth prospect risk po
soft spend biopharma consolid competit technolog risk execut
risk regulatori risk
po base adj ebitda estim line compani
two-year forward ev/ebitda multipl last three year upsid risk better
expect growth high-valu product result higher organ revenu growth
margin expans stronger expect fx tailwind acquisit
compani downsid risk advers custom suppli chain swing slower
expect adopt new product due time stability/valid studi
volatil raw materi cost currenc low capac util
juan avendano derik de bruin herebi certifi view us
express research report accur reflect respect person
view subject secur issuer also certifi part
respect compens directli indirectli relat specif
recommend view express research report
